fbpx

Dr. Reddy’s Laboratories defends its right to launch Buprenorphine and Naloxone Sublingual Film in the U.S. Market

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY)
announced today that following the launch of its generic Buprenorphine
and Naloxone Sublingual Film in the U.S. Market, the U.S. District Court
for the District of New Jersey has received and reviewed an emergency
application from the plaintiffs in the current patent litigation for a
temporary restraining order and preliminary injunction against Dr.
Reddy’s.

Pending a hearing and decision on the injunction application, the court
has issued a temporary restraining order against Dr. Reddy’s with
respect to further sales and commercialization of Buprenorphine and
Naloxone Sublingual Film within the U.S. The court order does not
include a prohibition on commercial manufacturing of the product. The
plaintiffs will be required to post a bond or other security totaling
$18 million (USD) to satisfy any losses or damages incurred by Dr.
Reddy’s during the period of the temporary restraining order. The court
has scheduled an expedited hearing of the preliminary injunction for
Thursday, June 28, and a ruling is expected soon thereafter. The
proceeding only involves one patent, U.S. Patent No. 9,931,305. Dr.
Reddy’s remains confident in its legal positions on this patent and
believes it will prevail on the issues raised with respect to the
application for injunction.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124,
NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company,
committed to providing affordable and innovative medicines for healthier
lives. Through its three businesses – Pharmaceutical Services & Active
Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s
offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. Our major therapeutic areas of focus are gastrointestinal,
cardiovascular, diabetology, oncology, pain management and dermatology.
Dr. Reddy’s operates in markets across the globe. Our major markets
include – USA, India, Russia & CIS countries, and Europe. For more
information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on the
management’s current views and assumptions and involve known or unknown
risks and uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in such
statements. In addition to statements which are forward-looking by
reason of context, the words “may”, “will”, “should”, “expects”,
“plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”,
“potential”, or “continue” and similar expressions identify
forward-looking statements. Actual results, performance or events may
differ materially from those in such statements due to without
limitation, (i) general economic conditions such as performance of
financial markets, credit defaults , currency exchange rates , interest
rates , persistency levels and frequency / severity of insured loss
events (ii) mortality and morbidity levels and trends, (iii) changing
levels of competition and general competitive factors, (iv) changes in
laws and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization ,
including related integration issues.

The company assumes no obligation to update any information contained
herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180615005867/en/